Sage Therapeutics, Inc. (SAGE) shares rallied 12.2% in the last trading session to close at $5.61. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.1% gain over the past four weeks.The company recently announced a strategic reorganization wherein it decided to focus on the commercialization of its depression drug Zurzuvae (zuranolone), which is marketed in partnership with Biogen. Zurzuvae is the first and o ...

Sage Therapeutics’ (SAGE) phase II study evaluating its neuropsychiatric candidate, dalzanemdor (SAGE-718), for treating cognitive impairment (CI) associated with Huntington’s Disease (HD) failed to meet the primary endpoint.The double-blind, placebo-controlled DIMENSION study evaluated the effects of dalzanemdor in participants with CI associated with HD.Top-line data from the study showed that dalzanemdor failed to demonstrate a statistically significant difference from baseline compared to placebo on the ...

Sage Therapeutics, Inc. (SAGE) reported a loss of $1.53 per share for the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.52. The company had reported a loss of $2.81 per share (excluding the restructuring expenses) in the year-ago quarter. Revenues in the third quarter totaled $11.8 million, significantly up from $2.7 million reported in the year-ago period. The upside can be attributed to sales of new depression drug Zurzuvae (zuranolone), which is marketed in partnership wi ...

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Katie Plante - Manager of Investor Relations Barry E. Greene - Chief Executive Officer Chris Benecchi - Chief Business Officer Laura Gault - Chief Medical Officer Kimi Iguchi - Chief Financial Officer Mike Quirk - Chief Scientific Officer Conference Call Participants Anupam Rama - J.P. Morgan Salveen Richter - Goldman Sachs Yasmeen Rahimi - Piper Sandler Jay Olson - Oppenheimer Ami Fadia - ...

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.52. This compares to loss of $2.81 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -0.66%. A quarter ago, it was expected that this company would post a loss of $1.68 per share when it actually produced a loss of $1.70, delivering a surprise of -1.19%. Over the last four quarters, the company ha ...

NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 and July 23, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline. SO WHAT: If you purchased Sage securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE). Shareholders who purchased shares of SAGE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sage-therapeutics-loss-submission-form/?id=109166&from=3 CLASS PERIOD: Apr ...

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 and July 23, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline. SO WHAT: If you purchased Sage securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Sage Therapeutics, Inc. (SAGE) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released ...

NEW YORK, Oct. 19, 2024 (GLOBE NEWSWIRE) -- WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 and July 23, 2024, both dates inclusive (the "Class Period"), of the important October 28, 2024 lead plaintiff deadline. SO WHAT: If you purchased Sage securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WH ...